Sign up
Pharma Capital

ReNeuron's Michael Hunt on 'very significant' exosome therapy data

Michael Hunt, CFO for ReNeuron Group Plc (LON:RENE), explains to Proactive their latest research which has been presented at a conference in Canada - highlighting the ability of their exosome therapy candidate to target specific organs of the body.


View full RENE profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.